Evidence map›Paper›PMID 37941436›Full record

ArticleJournal of Crohn's & colitis2024

Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib.

Zhigang Liu, James L Alexander, Kai Yee Eng, Hajir Ibraheim, Sulak Anandabaskaran, Aamir Saifuddin, Laura Constable, Rocio Castro Seoane, Claire Bewshea, Rachel Nice and 23 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Crohn's & colitis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 13 institutions in 1 country.

Zhigang LiuDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.ORCID 0000-0002-1363-6708
James L AlexanderDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.ORCID 0000-0001-8542-327X
Kai Yee EngDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Hajir IbraheimDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Sulak AnandabaskaranDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Aamir SaifuddinDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Laura ConstableDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Rocio Castro SeoaneDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Claire BewsheaExeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.ORCID 0000-0002-0965-9587
Rachel NiceExeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.
Andrea D'MelloDivision of Medicine & Integrated Care, Imperial College Healthcare NHS Trust, London, UK.
Gareth R JonesDepartment of Gastroenterology, Western General Hospital, NHS Lothian, Edinburgh, UK.
Sharmili BalarajahDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Francesca FiorentinoDepartment of Surgery and Cancer, Imperial College London, London, UK.
Shaji SebastianDepartment of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK.ORCID 0000-0002-3670-6545
Peter M IrvingDepartment of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Lucy C HicksDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Horace R T WilliamsDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Alexandra J KentDepartment of Gastroenterology, King's College Hospital, London, UK.
Rachel LingerThe NIHR Bioresource, University of Cambridge, Cambridge, UK.
Miles ParkesThe NIHR Bioresource, University of Cambridge, Cambridge, UK.
Klaartje KokDepartment of Gastroenterology, Bart's Health NHS Trust, London, UK.
Kamal V PatelDepartment of Gastroenterology, St George's Hospital NHS Trust, London, UK.
Julian P TeareDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Daniel M AltmannDepartment of Immunology and Inflammation, Imperial College London, London, UK.
Rosemary J BoytonDepartment of Infectious Disease, Imperial College London, London, UK.
Ailsa L HartDepartment of Gastroenterology, St Marks Hospital and Academic Institute, Gastroenterology, London, UK.
Charlie W LeesDepartment of Gastroenterology, Western General Hospital, NHS Lothian, Edinburgh, UK.
James R GoodhandExeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.
Nicholas A KennedyExeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.
Katrina M PollockDepartment of Infectious Disease, Imperial College London, London, UK.ORCID 0000-0001-9513-5183
Tariq AhmadExeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.ORCID 0000-0002-6058-5528
Nick PowellDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Imperial College Healthcare NHS Trust · GBImperial College London · GBUniversity of Exeter · GBSt Mark's Hospital · GBKing's College London · GBNHS Lothian · GBUniversity of Cambridge · GBBarts Health NHS Trust · GBGuy's and St Thomas' NHS Foundation Trust · GBKing's College Hospital · GBNIHR Imperial Biomedical Research Centre · GBSt George's Hospital · GBUniversity of Hull · GB

Funding

Medical Research Council MR/S034919/1Medical Research Council MR/W020610/1Medical Research Council MR/W024977/1Wellcome Trust
6 · The paper itself

Abstract

BACKGROUND AND

aimsWe sought to determine whether six commonly used immunosuppressive regimens were associated with lower antibody responses after seasonal influenza vaccination in patients with inflammatory bowel disease [IBD].

methodsWe conducted a prospective study including 213 IBD patients and 53 healthy controls: 165 who had received seasonal influenza vaccine and 101 who had not. IBD medications included infliximab, thiopurines, infliximab and thiopurine combination therapy, ustekinumab, vedolizumab, or tofacitinib. The primary outcome was antibody responses against influenza/A H3N2 and A/H1N1, compared to controls, adjusting for age, prior vaccination, and interval between vaccination and sampling.

resultsLower antibody responses against influenza A/H3N2 were observed in patients on infliximab (geometric mean ratio 0.35 [95% confidence interval 0.20-0.60], p = 0.0002), combination of infliximab and thiopurine therapy (0.46 [0.27-0.79], p = 0.0050), and tofacitinib (0.28 [0.14-0.57], p = 0.0005) compared to controls. Lower antibody responses against A/H1N1 were observed in patients on infliximab (0.29 [0.15-0.56], p = 0.0003), combination of infliximab and thiopurine therapy (0.34 [0.17-0.66], p = 0.0016), thiopurine monotherapy (0.46 [0.24-0.87], p = 0.017), and tofacitinib (0.23 [0.10-0.56], p = 0.0013). Ustekinumab and vedolizumab were not associated with reduced antibody responses against A/H3N2 or A/H1N1. Vaccination in the previous year was associated with higher antibody responses to A/H3N2. Vaccine-induced anti-SARS-CoV-2 antibody concentration weakly correlated with antibodies against H3N2 [r = 0.27; p = 0.0004] and H1N1 [r = 0.33; p < 0.0001].

conclusionsVaccination in both the 2020-2021 and 2021-2022 seasons was associated with significantly higher antibody responses to influenza/A than no vaccination or vaccination in 2021-2022 alone. Infliximab and tofacitinib are associated with lower binding antibody responses to influenza/A, similar to COVID-19 vaccine-induced antibody responses.

Indexed as

Inflammatory Bowel DiseasesInfliximabInfluenza VaccinesPiperidinesPyrimidinesAdultAntibodies, ViralAntibody FormationCase-Control StudiesFemaleHumansImmunosuppressive AgentsInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza, HumanMaleAntibodies, ViralImmunosuppressive AgentsInfliximabInfluenza VaccinesPiperidinesPyrimidinestofacitinibanti-TNFhumoral immunityimmunisationJAK-inhibitor

Identifiers

PMID37941436
PMCPMC11037107
OpenAlexW4388538888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.